Clinical trials: Drug Eluting Stents
Coronary Artery Disease, Platelet Aggregation Inhibitors
Plavix, Prasugrel and Drug Eluting Stents Pilot Trial
The purpose of this study is to determine the level of inhibition of platelet activation of an approved thienopyridine(clopidogrel or prasugrel) and aspirin regimen in the setting of drug eluting coronary stent implantation.
- Conditions
- Coronary Artery Disease, Platelet Aggregation Inhibitors, PCI- Percutaneous Coronary Intervention
- Trial name
- PPD (NCT01103843)
- Testing
- Loading Dose Arm, Maintenance Dose Arm
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- St. Francis Hospital, New York
Peripheral Vascular Diseases
Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery
The Zilver® PTX™ Drug Eluting Vascular Stent is indicated for the treatment of symptomatic vascular disease of the above-the-knee femoropopliteal artery (ranging from 4 mm to 9 mm in reference vessel diameter) for lesions up to 7…
- Trial name
- Zilver PTX (NCT00120406)
- Testing
- Zilver® PTX™ Drug Eluting Vascular Stent, Angioplasty
- Where
- 52 sites in United States, Germany and 1 more
- Volunteers
- 474 people
- Sponsor
- Cook Group Incorporated
Gastrointestinal Injury, Ischemic Heart Disease
Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation
Long-term DAPT is recommended after percutaneous coronary intervention (PCI) in patients with coronary artery disease. However, antiplatelet therapy may have adverse consequences, the most common of which is gastrointestinal…
- Trial name
- OPT-PEACE (NCT03198741)
- Testing
- Aspirin + clopidogrel, Clopidogrel monotherapy, Aspirin monotherapy
- Where
- China
- Volunteers
- 783 people
- Sponsor
- Shenyang Northern Hospital
Coronary Arterial Disease (CAD), Vulnerable Coronary Plaques
Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques
The aim of this clinical trial is to explore the optimal preventative treatment strategy for non-flow-limiting vulnerable plaques.
- Conditions
- Coronary Arterial Disease (CAD), Vulnerable Coronary Plaques, Thin-cap fIbroatheroma, Acute Coronary Syndromes (ACS)
- Trial name
- NCT06855537
- Testing
- PCI strategy, OMT strategy
- Where
- China
- Volunteers
- 2,190 people
- Sponsor
- Beijing Anzhen Hospital
Coronary Artery Disease
Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation
The purpose of this study is to compare short-term (6-month Dual Anti Platelet Therapy(DAPT) followed by clopidogrel monotherapy) vs.
- Trial name
- STAMP-DES (NCT02494284)
- Testing
- Clopidogrel, Aspirin plus clopidogrel
- Where
- 12 sites in South Korea
- Volunteers
- 364 people
- Sponsor
- CHEOL WHAN LEE, M.D., Ph.D
In Stent Restenosis, Drug Eluting Stent
A Comparison Between FFR Guided and CAG Guided Treatment Using DEB in ISR of DES
This is a prospective single center, randomized controlled clinical study aimed to compare the clinical and angiographic follow-up results of patients with in-stent restenosis(ISR) after coronary drug eluting stent(DES)…
- Conditions
- In Stent Restenosis, Drug Eluting Stent, Coronary Artery Disease
- Trial name
- NCT04518826
- Testing
- fractional flow reserve
- Volunteers
- 420 people
- Sponsor
- Shanghai Zhongshan Hospital
Saphenous Vein Graft Atherosclerosis
Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty
Patients who have undergone coronary bypass surgery have had a vein removed from the leg and implanted in the chest to "bypass" blockages in the coronary arteries. These veins are called saphenous vein grafts or SVGs.
- Trial name
- DIVA (NCT01121224)
- Testing
- Bare Metal Stent, Drug-Eluting Stent, Blinded clopidogrel
- Where
- 25 sites in United States
- Volunteers
- 597 people
- Sponsor
- VA Office of Research and Development
Coronary Artery Disease
Cynergy: the CYPHER-NEVO Registry
The purpose of this registry is to compare the safety and the performance of the NEVO™ Sirolimus-eluting Coronary Stent, once commercially available, to the CYPHER Select® Plus Sirolimus-eluting Coronary Stent in complex subjects…
- Trial name
- CYNERGY (NCT01106378)
- Where
- 3 sites in Brazil, South Korea and 1 more
- Volunteers
- 14,000 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
Association of Clopidogrel Therapy and Stent Thrombosis
The purpose of REAL-LATE (Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated with Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events) trial is to assess the relationship…
- Trial name
- REAL-LATE (NCT00484926)
- Testing
- Aspirin monotherapy, Aspirin,Clopidogrel
- Where
- 13 sites in South Korea
- Volunteers
- 2,000 people
- Sponsor
- Seung-Jung Park
Bioresorbable Scaffolds
Performance of Bioabsorbable Vascular Scaffolds (Absorb) Compared to Xience Stents - an Optical Coherence Tomography Study
The biodegradable ABSORB scaffold is characterized by a greater strut thickness, but it has a greater flexibility compared to the XIENCE stent.
- Trial name
- NCT02001025
- Testing
- Absorb scaffold, Xience stent
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Rudolf Berger
Coronary Disease
The Efficacy of Three Different Limus Agent-Eluting Stents to Prevent Restenosis
The purpose of this study is to evaluate the efficacy of 3 different drug-eluting-stent platforms to reduce coronary artery reblockage after stent implantation
- Trial name
- ISAR-TEST-2 (NCT00332397)
- Testing
- Rapamycin-eluting Stent, Zotarolimus-eluting Stent
- Where
- 2 sites in Germany
- Volunteers
- 1,007 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Artery Disease
New-DES vs BMS in SVG -1 Year Outcomes
Data regarding the efficacy of the percutaneous coronary intervention (PCI) with new-designed drug-eluting stent (new-DES) vs. bare metal stent (BMS) of saphenous vein grafts (SVG) stenosis is scarce.
- Trial name
- BALTIC (NCT04338308)
- Testing
- new-DES, BMS
- Where
- 3 sites in Poland
- Volunteers
- 792 people
- Sponsor
- Medical University of Silesia
Coronary Artery Disease
Drug-Coated Balloon in Combination With New Generation Drug-Eluting Stent for de Novo Diffuse Disease Treatment
A Pilot Observational Study to evaluate safety and efficacy of the hybrid approach DES/DCB in treating de-novo diffuse lesions
- Trial name
- HYPER (NCT03939468)
- Testing
- DES+DCB
- Where
- 6 sites in Italy
- Volunteers
- 106 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Coronary Artery Diseases
BIOFLOW-III UK Satellite Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
- Trial name
- NCT02257710
- Testing
- Orsiro
- Where
- 4 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Biotronik UK Ltd.
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Romania Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01593059
- Where
- 4 sites in Romania
- Volunteers
- 13 people
- Sponsor
- Biotronik Vertriebs-GmbH
Peripheral Arterial Disease
PacLitaxel Eluting Balloon Application In Sfa In Stent Restenosis
Nowadays, stenting is became a standard of care in revascularization for superficial femoral artery (SFA) atherosclerotic lesions. However, the Achilles' heel of this technique remains in-stent restenosis (ISR).
- Trial name
- PLAISIR (NCT01587482)
- Testing
- PacLitaxel Eluting Balloon Application
- Where
- France
- Volunteers
- 53 people
- Sponsor
- Nantes University Hospital
Acute Myocardial Infarction
Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial Infarction
The DEBATER study is designed to determine the superiority of abciximab over no abciximab and to determine the superiority of drug eluting stents over bare metal stents in patients with acute myocardial infarction who undergo…
- Trial name
- DEBATER (NCT00986050)
- Testing
- Abciximab, bare metal stent prokinetic, chrono, skylor or bluemedical, drug eluting stent (sirolimus eluting) - CYPHER stent
- Where
- Netherlands
- Volunteers
- 907 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Coronary Artery Disease
A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)
EVOLVE 48 is a prospective, open label, single arm, multi-center trial. The purpose of this study is to assess the FDA requirement for safety and effectiveness of the SYNERGY 48 mm Coronary Stent System for the treatment of…
- Trial name
- EVOLVE48 (NCT03350542)
- Testing
- SYNERGY 48 mm
- Where
- 15 sites in United States, Latvia and 2 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Restenosis
SEDUCE OCT Study in Coronary Artery rEstenosis:an Optical Coherence Tomography (OCT) Study
Different healing responses after treatment of bare metal stent restenosis with implantation of an everolimus-eluting Xience V stent (Abbott Vascular) versus use of a paclitaxel-eluting SeQuent Please balloon (BBraun): an optical…
- Trial name
- SEDUCE (NCT01065532)
- Testing
- Sequent Please Paclitaxel eluting balloon, Xience V everolimus eluting stent
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Coronary Artery Disease
Comparison of Optical Coherence Tomographic Findings After Balloon Angioplasty With Two Different Paclitaxel-Coated Balloons for the Treatment of In-Stent Restenosis in Drug-Eluting Stents
Drug-coated balloon technology (DCB) has recently attracted considerable interest as a promising alternative treatment option, particularly in the setting of in-stent restenosis (ISR).
- Trial name
- NCT02528474
- Testing
- balloon angioplasty with Pantera Lux, balloon angioplasty with SeQuent Please
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Yonsei University